Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Subscribe now